Finance

Lists
Why is TVTX up 2.99%?
Dive Deeper
TVTX:NASDAQ
Travere Therapeutics Inc
$61.22
+2.99%
(+1.78) 1D
Sep 28, 1:39:53 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TVTX...
Open
$59.05
High
$61.59
Low
$58.71
Mkt. cap
5.77B
Avg. vol.
1.44M
Volume
406.46K
52-wk high
$68.73
52-wk low
$22.06
EPS
-$0.50
Beta
1.05
Shares outstanding
94.26M
No. of employees
497
Open
$59.05
High
$61.59
Low
$58.71
Mkt. cap
5.77B
Avg. vol.
1.44M
Volume
406.46K
52-wk high
$68.73
52-wk low
$22.06
EPS
-$0.50
Beta
1.05
Shares outstanding
94.26M
No. of employees
497
News stories
From web sources and news partners
About Travere Therapeutics Inc
CEO-
Employees497
Founded2011
Headquarters-
SectorBiotechnology
Websitetravere.com
Analyst ratings
Based on 12 analysts giving stock ratings to TVTX in the past 3 months
Strong buy
Buy
11
Hold
1
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for TVTX in the last 3 months.
Highest
Current $61.22
$90.00 (+47.01%)
Average
$75.92 (+24.01%)
Lowest
$62.00 (+1.27%)
Analyst
Recommendation
Action
Price target
Projected
Date
Vamil Divan
Guggenheim
Buy
Reiterated
$89.00
+45.4%
09/23/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
$71.00
+16%
09/23/2026
Laura Chico
Wedbush
Buy
Maintained
$76.00
+24.1%
09/22/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$67.00
+9.4%
09/23/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$68.00
+11.1%
08/17/2026
Edward Nash
Canaccord Genuity
Buy
Maintained
$70.00
+14.3%
08/11/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$78.00
+27.4%
08/10/2026
Alex Thompson CFA
Stifel Nicolaus
Hold
Maintained
$62.00
+1.3%
08/09/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$90.00
+47%
08/06/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
$80.00
+30.7%
08/06/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$85.00
+38.8%
08/06/2026
Tyler Van Buren
TD Cowen
Buy
Reiterated
$75.00
+22.5%
08/04/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$50.00
-18.3%
05/06/2026
Unknown Analyst
Evercore ISI
Buy
Maintained
$52.00
-15.1%
05/05/2026
Prakhar Agrawal
Cantor Fitzgerald
Buy
Reiterated
-
-
02/20/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
164.86M
129.69M
127.20M
169.58M
Cost of goods sold
53.48M
60.42M
83.86M
69.52M
Cost of revenue
53.48M
60.42M
83.86M
69.52M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
86.45M
101.69M
80.25M
96.11M
Operating expense
86.45M
101.69M
80.25M
96.11M
Total operating expenses
139.93M
162.12M
164.11M
165.63M
Operating income
24.93M
-32.43M
-36.92M
3.95M
Other non operating income
487.00K
11.07M
-91.00K
-40.18M
EBT including unusual items
25.71M
-21.06M
-36.72M
-35.00M
EBT excluding unusual items
25.71M
-21.06M
-36.72M
-35.00M
Income tax expense
8.00K
921.00K
-120.00K
-204.00K
Effective tax rate
0.03%
-4.37%
0.33%
0.58%
Other operating expenses
-
-
-
-
Net income
25.71M
2.73M
-37.10M
-34.80M
Net profit margin
15.59%
2.10%
-29.17%
-20.52%
Earnings per share
0.59
0.37
0.05
-0.10
Interest and investment income
3.05M
2.59M
2.58M
3.36M
Interest expense
-2.75M
-2.30M
-2.30M
-2.13M
Net interest expenses
296.00K
296.00K
284.00K
1.22M
Depreciation and amortization charges
-
-
-
-
EBITDA
40.72M
-14.29M
-11.70M
8.19M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps